ATE487492T1 - Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit - Google Patents

Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit

Info

Publication number
ATE487492T1
ATE487492T1 AT04714961T AT04714961T ATE487492T1 AT E487492 T1 ATE487492 T1 AT E487492T1 AT 04714961 T AT04714961 T AT 04714961T AT 04714961 T AT04714961 T AT 04714961T AT E487492 T1 ATE487492 T1 AT E487492T1
Authority
AT
Austria
Prior art keywords
drug dependence
pharmaceutical composition
treating drug
treating
dependence
Prior art date
Application number
AT04714961T
Other languages
English (en)
Inventor
Shigetada Nakanishi
Takatoshi Hikida
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE487492T1 publication Critical patent/ATE487492T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT04714961T 2003-02-27 2004-02-26 Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit ATE487492T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44986803P 2003-02-27 2003-02-27
PCT/JP2004/002301 WO2004075916A1 (en) 2003-02-27 2004-02-26 Pharmaceutical composition for treatment of drug dependence

Publications (1)

Publication Number Publication Date
ATE487492T1 true ATE487492T1 (de) 2010-11-15

Family

ID=32927586

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04714961T ATE487492T1 (de) 2003-02-27 2004-02-26 Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit

Country Status (8)

Country Link
US (1) US20060058336A1 (de)
EP (1) EP1603595B1 (de)
JP (1) JP2006519225A (de)
AT (1) ATE487492T1 (de)
AU (1) AU2004216360B2 (de)
CA (1) CA2516618A1 (de)
DE (1) DE602004029993D1 (de)
WO (1) WO2004075916A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
WO2003032914A2 (en) * 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
WO2006013546A2 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Process for the preparation of pure galantamine
SG183696A1 (en) * 2007-08-06 2012-09-27 Biotie Therapies Inc Medicaments comprising nepicastat for use in treating dependence on a substance
KR101037235B1 (ko) 2009-04-24 2011-05-25 충남대학교산학협력단 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 방지 및 발모 개선용 조성물
KR101037237B1 (ko) 2009-04-24 2011-05-25 충남대학교산학협력단 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 질환의 예방 및 치료용 조성물
WO2010123184A1 (ko) * 2009-04-24 2010-10-28 제주대학교 산학협력단 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 질환의 예방 및 치료용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5262165A (en) * 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE69229781T2 (de) * 1991-05-14 2000-01-05 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE69533284T2 (de) * 1994-04-29 2005-07-21 Pfizer Inc. Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttung
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
HU228434B1 (en) * 1995-06-07 2013-03-28 Ortho Mcneil Pharm Inc Transdermal medicament for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5824684A (en) * 1997-02-21 1998-10-20 Synapse Pharmaceuticals International, Inc. Method for treating drug and alcohol addiction
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
EP1024807B1 (de) * 1997-08-08 2003-04-16 MEDOSAN RICERCA S.r.l. Verwendung von 2-methoxyphenyl-1-methyl-5p-methyl-benzoylpyrrol-2-acetamido-acetat zur herstellung eines antientzündungsmittels mit vorbeugung von magenhypersekretion und nierenfunktionsstörung
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
JP3992806B2 (ja) * 1997-12-12 2007-10-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 ドネペジル中間体の製造法
IL125809A (en) * 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
AU2001249091A1 (en) * 2000-03-03 2001-09-17 Eisai Co. Ltd. Novel methods using cholinesterase inhibitors
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
WO2002049459A1 (en) * 2000-12-20 2002-06-27 Michigan Biotechnology Institute Soy milk juice beverage
DE10119862A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
WO2003024450A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
WO2003032914A2 (en) * 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
JP2004189706A (ja) * 2002-12-13 2004-07-08 Eisai Co Ltd 高度アルツハイマー型痴呆治療剤
US20050018839A1 (en) * 2003-07-23 2005-01-27 Weiser William Bruce Electronic device cradle organizer

Also Published As

Publication number Publication date
EP1603595B1 (de) 2010-11-10
CA2516618A1 (en) 2004-09-10
AU2004216360A1 (en) 2004-09-10
EP1603595A1 (de) 2005-12-14
DE602004029993D1 (de) 2010-12-23
AU2004216360A2 (en) 2004-09-10
AU2004216360B2 (en) 2009-09-17
US20060058336A1 (en) 2006-03-16
JP2006519225A (ja) 2006-08-24
WO2004075916A1 (en) 2004-09-10
EP1603595A4 (de) 2008-04-16

Similar Documents

Publication Publication Date Title
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
BRPI0415858A (pt) compostos de medicamentos terapêuticos modificados por tocoferol
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
EA200501702A1 (ru) Устойчивая к манипуляциям дозировочная форма для трансдермального введения
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
ATE486634T1 (de) Caspase 3, 8, 9 oder 10 inhibitoren in kombination mit mek inhibitoren zur behandlung von influenza
ATE550015T1 (de) Verfahren und zusammensetzung zur behandlung von rhinitis
DE60326069D1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
ATE487492T1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
ATE413171T1 (de) Pharmazeutische zusammensetzungen mit ascorbinsäure zur behandlung von pilz- superinfektionen und pilz-rezidiven
DE50211212D1 (de) Pharmazeutische zubereitung enthaltend wirkstoffe aus den pflanzen centella asiatica, mahonia aquifolium und viola tricolor
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
AR040287A1 (es) Plataforma para formulaciones transdermicas (pft)
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
DE60322110D1 (de) Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten
BRPI0518554A2 (pt) uso de um inibidor de pde3
DE602004025103D1 (de) Heilkräuterzusammensetzung zur Behandlung von AIDS
ATE446763T1 (de) Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties